Califf's Priorities Will Reflect Both Short- And Long-Term Goals
This article was originally published in The Pink Sheet Daily
Newly confirmed FDA Commissioner should not assume he'll be leaving once new president arrives, Republican-appointed predecessor says.
You may also be interested in...
In an interview with “The Pink Sheet,” new deputy commissioner for medical products says FDA needs better ways of helping stakeholders, public understand agency thinking.
Acting FDA Commissioner says he can’t envision any new major priorities that would emerge in the short-term.
The mandates in the FDA Safety and Innovation Act and Drug Quality and Security Act show a lot of congressional confidence in the agency, but FDA commissioner says that members also must provide resources to go with it.